Thiazole analog as stearoyl-CoA desaturase 1 inhibitor.
SCD1 inhibition may represent a novel treatment for obesity, type-2 diabetes and related metabolic disorders. A prototype thiazole amide analog 13 (MF-152) was identified as an excellent tool in the study of SCD biology in animals.
Li
Chun Sing
CS
Merck Frosst Centre for Therapeutic Research, 16711 TransCanada Hwy, Kirkland, Quebec, Canada. chunsing_li@merck.com
Belair
Liette
L
Guay
Jocelyne
J
Murgasva
Renata
R
Sturkenboom
Wayne
W
Ramtohul
Yeeman K
YK
Zhang
Lei
L
Huang
Zheng
Z
D000284:Administration, Oral; D000818:Animals; D045744:Cell Line, Tumor; D004791:Enzyme Inhibitors / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology; D006801:Humans; D007004:Hypoglycemic Agents / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D010879:Piperazines / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology; D051381:Rats; D013230:Stearoyl-CoA Desaturase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013844:Thiazoles / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology
D004791:Enzyme Inhibitors; D007004:Hypoglycemic Agents; C544974:MF 152; D010879:Piperazines; D013844:Thiazoles; D013230:Stearoyl-CoA Desaturase